St. Jude Care & Treatment

Menu

Close

Recruiting

CARETPX: Repotrectinib for Tumors with Gene Changes

About this study 

Some cancers spread from the original tumor site to the area around it (advanced) or to other parts of the body (metastatic). These tumors may also have a change in 1 of the following genes: ALK, ROS1, NTRK1, NTRK2, or NTRK3.

These tumors are often treated with surgery, chemotherapy and/or radiation, or FDA-approved drugs. These treatments can help reduce the patient’s symptoms. They may also stop the tumor from growing for a few months or longer. But sometimes the tumor does not go away. Sometimes it gets worse.

This study will look at a new drug called repotrectinib. We are studying this drug as a possible treatment for advanced or metastatic solid tumors with a change in the ALK, ROS, or NTRK1–3 genes.

The purpose of this study is to look at the safety of repotrectinib in children and young adults. The study will also see whether this drug might work against tumors.

Eligibility overview 

  • Up to 25 years old
  • Cancer that has spread from the original solid tumor site
  • A change in 1 of these genes: ALK, ROS1, NTRK1, NTRK2, or NTRK3

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1–3 Alterations

Study goal:

To find out whether repotrectinib is safe to use in children and young adults and whether it might work against tumors.

Diagnosis:

Neuroblastoma, Wilms tumor, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, retinoblastoma, hepatoblastoma, medulloblastoma, germ cell tumors

Age:

Up to 25 years old

Clinical trials categories:

Solid Tumors Rhabdomyosarcoma Ewing Sarcoma Medulloblastoma Childhood Cancer Osteosarcoma Retinoblastoma Wilms Tumor Germ Cell Tumors (Solid Tumor) Neuroblastoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more